弥漫性大B细胞淋巴瘤化疗后外周血T细胞亚群的动态变化
Dynamic Changes in Peripheral Blood T-Cell Subset after Immunochemotherapy Treatment in Diffuse Large B-Cell Lymphoma
摘要: 引言:弥漫性大B细胞淋巴瘤(Diffuse large B-cell lymphoma,DLBCL)患者体内T淋巴细胞亚群的转化和分布与疾病进展有关。CD4+T细胞亚群在体内启动和调节抗淋巴瘤免疫应答中的作用仍有争议。方法:我们回顾性分析了31例DLBCL患者的临床资料,他们接受了六个周期的一线治疗方案,即利妥昔单抗联合环磷酰胺、多柔比星、长春新碱和泼尼松龙(R-CHOP)。我们分别在诊断和治疗后收集了这些患者的外周血样本,循环淋巴细胞亚群的百分比由定量流式细胞术分析得出。结果:我们记录了Th1细胞的逐渐增加,这在T3时是显著的,Th2和Treg细胞的减少一直维持到R-CHOP治疗的T3时期。两个周期的治疗已经诱导Th1/Th2比率显著增长,并从那时起持续增加。我们发现基线和T3时Th1/Th2比值与达到完全缓解(Complete Response, CR)之间存在显著相关性。Th1细胞百分比与CR实现之间存在相关性,Th1细胞的临界值为43.09。结论:我们认为,在新诊断的患者中,R-CHOP可能通过抑制Th2的扩增来改变Th1/Th2比值的转化,这表明在治疗期间T细胞极化从促肿瘤T细胞应答强烈转变为抗肿瘤T细胞反应。
Abstract: Introduction: The transformation and distribution of specific T-cell subsets in diffuse large B-cell lymphoma (DLBCL) patients are connected with disease progression. The role of CD4+T cell subsets in initiating and regulating anti-lymphoma immune response in vivo remains controversial. Meth-ods: We retrospectively analyzed the clinical data of 31 patients diagnosed with DLBCL who under-went six cycles of rituximab-cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) chemotherapy or more, serving as the first-line therapy. We collected peripheral blood samples from these patients at diagnosis and post-treatment, and analyzed the percentages of circulating lymphocyte subsets by quantitative flow cytometry. Results: We documented a progressive in-crease of Th1 cells, which was significant at T3, and a decrease of Th2 and Treg cells which was maintained up to T3 of R-CHOP treatment. Two cycles of treatment have already induced significant growth in the Th1/Th2 ratio and maintained a progressive increase since then. We found a signifi-cant correlation between the level of Th1/Th2 ratio at baseline and T3, and the realization of the complete response (CR). There was a correlation between the percentage of Th1 cells and the reali-zation of the CR, with the cut-off value of 43.09 of Th1 cells. Conclusion: We believe that in newly di-agnosed patients, R-CHOP may change the transformation of Th1/Th2 ratio by inhibiting the ampli-fication of Th2. This analysis showed that the higher Th1/Th2 ratio and the increase of Th1 cells significantly correlated with the CR achievement, which suggests a strong transformation of T-cell polarization from a pro- to an anti-tumor T-cell response during treatment.
文章引用:符铃遥, 张红宾. 弥漫性大B细胞淋巴瘤化疗后外周血T细胞亚群的动态变化[J]. 临床医学进展, 2023, 13(5): 7417-7428. https://doi.org/10.12677/ACM.2023.1351035

参考文献

[1] Lossos, I.S., Czerwinski, D.K., Alizadeh, A.A., et al. (2004) Prediction of Survival in Diffuse Large-B-Cell Lymphoma Based on the Expression of Six Genes. New England Journal of Medicine, 350, 1828-1837. [Google Scholar] [CrossRef
[2] Martelli, M., Ferreri, A.J., Agostinelli, C., Di Rocco, A., Pfreundschuh, M. and Pileri, S.A. (2013) Diffuse Large B-Cell Lymphoma. Critical Reviews in Oncology/Hematology, 87, 146-171. [Google Scholar] [CrossRef] [PubMed]
[3] Molina, A. (2008) A Decade of Rituximab: Improving Sur-vival Outcomes in Non-Hodgkin’s Lymphoma. Annual Review of Medicine, 59, 237-250. [Google Scholar] [CrossRef] [PubMed]
[4] Younes, A., Thieblemont, C., Morschhauser, F., et al. (2014) Combination of Ibrutinib with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) for Treatment-Naive Patients with CD20-Positive B-Cell Non-Hodgkin Lymphoma: A Non-Randomised, Phase 1b Study. The Lancet Oncology, 15, 1019-1026. [Google Scholar] [CrossRef
[5] Lossos, I.S. and Morgensztern, D. (2006) Prognostic Bi-omarkers in Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 24, 995-1007. [Google Scholar] [CrossRef
[6] Mociková, H. (2010) Prognostic Significance of Absolute Lym-phocyte Count and Lymphocyte Subsets in Lymphomas. Prague Medical Report, 111, 5-11. http://pmr.cuni.cz/Data/Files/PragueMedicalReport/pmr_111_2010_1/pmr2010a0001.pdf
[7] Galand, C., Donnou, S., Molina, T.J., Fridman, W.H., Fisson, S. and Sautès-Fridman, C. (2012) Influence of Tumor Location on the Composition of Immune Infiltrate and Its Impact on Patient Survival. Lessons from DCBCL and Animal Models. Frontiers in Immu-nology, 3, Article 98. [Google Scholar] [CrossRef] [PubMed]
[8] Wahlin, B.E., Sander, B., Christensson, B. and Kimby, E. (2007) CD8+ T-Cell Content in Diagnostic Lymph Nodes Measured by Flow Cytometry Is a Predictor of Survival in Follicular Lymphoma. Clinical Cancer Research, 13, 388-397. [Google Scholar] [CrossRef
[9] D’Arena, G., Vitale, C., Coscia, M., et al. (2017) Regulato-ry T Cells and Their Prognostic Relevance in Hematologic Malignancies. Journal of Immunology Research, 2017, Article ID: 1832968. [Google Scholar] [CrossRef] [PubMed]
[10] Kusano, Y., Yokoyama, M., Terui, Y., et al. (2017) Low Absolute Peripheral Blood CD4+ T-Cell Count Predicts Poor Prognosis in R-CHOP-Treated Patients with Diffuse Large B-Cell Lymphoma. Blood Cancer Journal, 7, e558. [Google Scholar] [CrossRef] [PubMed]
[11] Chraa, D., Naim, A., Olive, D. and Badou, A. (2019) T Lymphocyte Subsets in Cancer Immunity: Friends or Foes. Journal of Leukocyte Biology, 105, 243-255. [Google Scholar] [CrossRef
[12] Palma, M., Gentilcore, G., Heimersson, K., et al. (2017) T Cells in Chronic Lymphocytic Leukemia Display Dysregulated Expression of Immune Checkpoints and Activation Markers. Haematologica, 102, 562-572. [Google Scholar] [CrossRef] [PubMed]
[13] Dobrzanski, M.J. (2013) Expanding Roles for CD4 T Cells and Their Subpopulations in Tumor Immunity and Therapy. Frontiers in Oncology, 3, Article 63. [Google Scholar] [CrossRef] [PubMed]
[14] Fridman, W.H., Pagès, F., Sautès-Fridman, C. and Galon, J. (2012) The Immune Contexture in Human Tumours: Impact on Clinical Outcome. Nature Reviews Cancer, 12, 298-306. [Google Scholar] [CrossRef] [PubMed]
[15] Battella, S., Cox, M.C., La Scaleia, R., et al. (2017) Peripheral Blood T Cell Alterations in Newly Diagnosed Diffuse Large B Cell Lymphoma Patients and Their Long-Term Dynamics Upon Rituximab-Based Chemoimmunotherapy. Cancer Immunology, Immunotherapy, 66, 1295-1306. [Google Scholar] [CrossRef] [PubMed]
[16] Mori, T., Takada, R., Watanabe, R., Okamoto, S. and Ikeda, Y. (2001) T-Helper (Th)1/Th2 Imbalance in Patients with Previously Untreated B-Cell Diffuse Large Cell Lymphoma. Cancer Immunology, Immunotherapy, 56, 566-568. [Google Scholar] [CrossRef] [PubMed]
[17] Sheng, L., Fu, D., Ca,o Y., et al. (2022) Integrated Genomic and Transcriptomic Analyses of Diffuse Large B-Cell Lymphoma with Multiple Abnormal Immunologic Markers. Frontiers in Oncology, 12, Article 790720. [Google Scholar] [CrossRef] [PubMed]
[18] Abès, R., Gélizé, E., Fridman, W.H. and Teillaud, J.-L. (2010) Long-Lasting Antitumor Protection by Anti-CD20 Antibody through Cellular Immune Response. Blood, 116, 926-934. [Google Scholar] [CrossRef] [PubMed]
[19] Weiner, G.J. (2010) Rituximab: Mechanism of Action. Semi-nars in Hematology, 47, 115-123. [Google Scholar] [CrossRef] [PubMed]
[20] Yin, Q., Zha, X., Yang, L., et al. (2011) Generation of Diffuse Large B Cell Lymphoma-Associated Antigen-Specific Vα6/Vβ13+T Cells by TCR Gene Transfer. Journal of Hematology & Oncology, 4, Article No. 2.
https://Doi.Org/10.1186/1756-8722-4-2
[21] Schreck, S., Friebel, D., Buettner, M., et al. (2009) Prognostic Impact of Tumour-Infiltrating Th2 and Regulatory T cells in Classical Hodgkin Lymphoma. Hematological Oncology, 27, 31-39. [Google Scholar] [CrossRef] [PubMed]
[22] Dehghani, M., Ramzi, M., Kalani, M., Golmoghaddam, H. and Arandi, N. (2022) Higher Peripheral Blood IFN-γ-/IL-4+ Th2 Lymphocytes Are Associated with Lower Rate of Relapse in Patients with Lymphoma. Immunological Investigations, 51, 452-463. [Google Scholar] [CrossRef] [PubMed]
[23] Yoon, N.K., Maresh, E.L., Shen, D., et al. (2010) Higher Levels of GATA3 Predict Better Survival in Women with Breast Cancer. Human Pathology, 41, 1794-1801. [Google Scholar] [CrossRef] [PubMed]
[24] Lorvik, K.B., Hammarström, C., Fauskanger, M., et al. (2016) Adoptive Transfer of Tumor-Specific Th2 Cells Eradicates Tumors by Triggering an in Situ Inflammatory Immune Re-sponse. Cancer Research, 68, 64-76. [Google Scholar] [CrossRef
[25] Purwar, R., Schlapbach, C., Xiao, S., et al. (2012) Robust Tumor Immunity to Melanoma Mediated by Interleukin-9-Producing T Cells. Nature Medicine, 18, 1248-1253. [Google Scholar] [CrossRef] [PubMed]
[26] Jones, E.A., Pringle, J.H., Angel, C.A. and Rees, R.C. (2002) Th1/Th2 Cy-tokine Expression and Its Relationship with Tumor Growth in B Cell Non-Hodgkin’s Lymphoma (NHL). Leukemia & Lymphoma, 43, 1313-1321. [Google Scholar] [CrossRef] [PubMed]
[27] Kurtz, D.M., Tschetter, L.K., Allred, J.B., et al. (2007) Subcuta-neous Interleukin-4 (IL-4) for Relapsed and Resistant Non-Hodgkin Lymphoma: A Phase II Trial in the North Central Cancer Treatment Group, NCCTG 91-78-51. Leukemia & Lymphoma, 48, 1290-1298. [Google Scholar] [CrossRef] [PubMed]
[28] Yin, Q., Chen, L., Li, Q., et al. (2014) Changes of T-Lymphocyte Subpopulation and Differential Expression Pattern of the T-Bet and GATA-3 Genes in Diffuse Large B-Cell Lymphoma Patients after Chemotherapy. Cancer Cell International, 14, Article No. 85. [Google Scholar] [CrossRef] [PubMed]
[29] Deligne, C., Metidji, A., Fridman, W.-H. and Teillaud, J.-L. (2015) Anti-CD20 Therapy Induces a Memory Th1 Response through the IFN-γ/IL-12 Axis and Prevents Protumor Regulatory T-Cell Expansion in Mice. Leukemia, 29, 947-957. [Google Scholar] [CrossRef] [PubMed]
[30] Puzzolo, M.C., Del Giudice, I., Peragine, N., et al. (2021) TH2/TH1 Shift under Ibrutinib Treatment in Chronic Lymphocytic Leukemia. Frontiers in Oncology, 11, Article 637186. [Google Scholar] [CrossRef] [PubMed]
[31] Chang, C., Wu, S.-Y., Kang, Y.-W., et al. (2015) High Levels of Regulatory T Cells in Blood Are a Poor Prognostic Factor in Patients with Diffuse Large B-Cell Lymphoma. American Journal of Clinical Pathology, 144, 935-944. [Google Scholar] [CrossRef
[32] Tzankov, A., Meier, C., Hirschmann, P., Went, P., Pileri, S.A. and Dirnhofer, S. (2008) Correlation of High Numbers of Intratumoral FOXP3+ Regulatory T Cells with Improved Survival in Germinal Center-Like Diffuse Large B-Cell Lymphoma, Follicular Lymphoma and Classical Hodgkin’s Lymphoma. Haematologica, 93, 193-200. [Google Scholar] [CrossRef] [PubMed]
[33] Dehghani, M., Kalani, M., Golmoghaddam, H., Ramzi, M. and Arandi, N. (2020) Aberrant Peripheral Blood CD4+ CD25+ FOXP3+ Regulatory T Cells/T Helper-17 Number Is Associated with the Outcome of Patients with Lymphoma. Cancer Immunology, Immunotherapy, 69, 1917-1928. [Google Scholar] [CrossRef] [PubMed]